Refractory Tumor

15 registered clinical trials studyying Refractory Tumor — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC NCT06456138	Shanghai Chest Hospital	Phase 1 / Phase 2
Completed	A Study of DCR-STAT3 in Adults With Solid Tumors NCT06098651	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	Phase 1
Unknown	A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Ref NCT06047860	Second Affiliated Hospital of Soochow University	Phase 2
Unknown	Neoantigen Derived DCs as Cancer Treatment NCT05767684	National Health Research Institutes, Taiwan	Phase 1
Unknown	Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors NCT05790447	Second Affiliated Hospital of Soochow University	Phase 2
Recruiting	Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumou NCT05752552	DeuterOncology	Phase 1
Completed	Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resista NCT06202599	Peking University People's Hospital	—
Unknown	Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors NCT04900519	Sorrento Therapeutics, Inc.	Phase 1
Terminated	Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Met NCT05099549	NKGen Biotech, Inc.	Phase 1 / Phase 2
Withdrawn	Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors NCT04809012	Sorrento Therapeutics, Inc.	Phase 2
Terminated	9-ING-41 in Pediatric Patients With Refractory Malignancies. NCT04239092	Actuate Therapeutics Inc.	Phase 1
Unknown	Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 NCT03158324	National University Hospital, Singapore	Phase 2
Unknown	Efficacy and Safety of Precision Therapy in Refractory Tumor NCT03239015	Baodong Qin	Phase 2
Completed	A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors NCT02564198	Eli Lilly and Company	Phase 1
Completed	Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts NCT03415477	Peking University People's Hospital	Phase 1 / Phase 2